I personally haven't heard or interpreted that, but these guys wouldn't communicate that even if they desperately wanted it. :)
I have had the impression that ENTA sees itself as a source of discovery of compounds and has the ability to deliver them to partners to develop, or to sell them, or what is recently being developed that with income from royalties (wave 1 ABT-450, Wave 2 Japan 2DAA program, Wave 3-ABT- 493 royalties, ENTA can start development of several other compounds (NASH, Nuke, NS5A. Cyclophillin inhib), and perhaps become a player in the HCV market.
I've never heard Luly encourage thoughts about being bought out, he also always talks about what a mutually beneficial relationship ENTA has had with ABBV/ABT.
There are enough catalysts ahead that I think share price may pop up once treatment numbers are known, Japan comes on line, Europe deals are set, 2nd gen data is released (they say starts phase 3 end of this year)
TO EXPAND on this; analysts see income sharply peaking and dropping for ENTA in 2016/17 time frame.
IF the 2nd gen program prevails they will not only be guarenteed a long stream of royalties, but also will be making almost double streams of income for the 1st and 2nd generation programs concurrently; much like Gilead is experiencing with Sovaldi and Harvoni.
I think that could be a pretty big deal, and it seems to fly in the face of what some analysts are predicting.(which may be either very objective, or very shortsighted) : )
We will see.
It could be that traders want a buyout and investors want a long term relationship. All I have seen seems to support the latter for what Abbvie and ENTA both want.
If one can read the tea leaves...what does it say that the ENTA float hasn't changed much and that there has been very light insider selling? It seems to me that ACHN has been courting suitors, investors. ENTA doesn't seem to be doing that.
Market Data 
Markets 
AI
